PTO/SB/08 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Apperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO
INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

Date Submitted: September 22, 2009

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known				
Application Number	10/573,882			
Filing Date	September 27, 2004			
First Named Inventor	Lutz F. SCHWEIGER			
Art Unit	1624			
Examiner Name	BRIAN E. MCDOWELL			
Attorney Docket Number	088736-0113			

U.S. PATENT DOCUMENTS					
Examin er Cite No.1	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
	1 4 1	Number-Kind Code ² (if known)			Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C1	BENDER, D. et al., "Synthesis of n.c.a. Carbon-11 Labelled Clozapine and its Major Metabolite Clazapine-N-oxide and Comparison of their Biodistribution of Mice", <i>Nucl. Med. Biol.</i> , vol. 21, no. 7, pp. 921-925, 1994.	
	C2	CHAKRABORTY, Paula K., et al., "High Yields Synthesis of High Specific Activity R-(—)- [¹¹C]Epinephrine of Routine PET Studies in Humans", Nucl. Med. Biol., vol. 20, no. 8, pp. 939-944, 1993.	
	C3	NAGEN, Kjell, et al., "Comparison of [11C]Methyl Triflate and [11C]Methyl lodide in the Synthesis of PET Radioligands such as [11C]β-CIT and [11C]βCFT", Nucl. Med. Biol., vol. 22, no. 8, pp. 965-970, 1995.	

Examiner Signature	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.